Wellgistics Health Inc(US:WGRX) Accessnewswire·2026-03-23 13:05Core Viewpoint - Wellgistics Health Inc. has signed a $105 million Letter of Intent to evaluate a potential acquisition of Neuritek Therapeutics, which specializes in innovative therapies for neurological and psychiatric disorders [1][2]. Group 1: Acquisition Details - The proposed transaction is an all-stock deal aimed at enhancing Wellgistics' healthcare platform by expanding capabilities related to its core pharmacy distribution and services business [2]. - The acquisition is expected to strengthen the alignment between drug development and commercialization, improve pipeline visibility, and support incremental revenue opportunities [2]. - The transaction is subject to due diligence, negotiation, board approvals, and other customary closing conditions, with no assurance that a definitive agreement will be reached [3]. Group 2: Company Overview - Wellgistics Health is a technology-driven healthcare platform that integrates wholesale distribution, prescription fulfillment, and AI-driven patient access solutions [5][6]. - The company aims to capture significant market share in the fragmented healthcare sector by expanding high-margin revenue streams and deepening relationships with manufacturers [6]. Group 3: Neuritek Therapeutics Overview - Neuritek Therapeutics has developed a next-generation treatment for Post-Traumatic Stress Disorder (PTSD), which is an orally active inhibitor of fatty acid amide hydrolase type 1 (FAAH1) [8]. - The company was founded by Dr. William Hapworth, a psychiatrist with over 30 years of clinical research experience [8].